Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 2/20 | 0.41 |
| ▸ | IDO1 | P14902 | 7/20 | 0.39 |
| ▸ | TDO2 | P48775 | 3/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13989353 | 0.92 | MAPT (0.46) | MAPTKDM4EGAAL3MBTL1GSK3B | |
| SCHEMBL13989366 | 0.91 | MAPT (0.41) | MAPTKDM4EGAAL3MBTL1GSK3B | |
| SCHEMBL13989295 | 0.90 | IDO1 (0.43) | MAPTKDM4EGAAL3MBTL1GSK3B | |
| SCHEMBL13989346 | 0.89 | MAPT (0.49) | MAPTKDM4EGAAL3MBTL1GSK3B | |
| Hydrochloric Acid SCHEMBL4879602 | 0.89 | IDO1 (0.43) | MAPTKDM4EGAAL3MBTL1GSK3B | |
| SCHEMBL13989350 | 0.88 | MAPT (0.39) | MAPTKDM4EGAAL3MBTL1GSK3B | |
| SCHEMBL13989363 | 0.86 | MAPT (0.41) | MAPTKDM4EGAAL3MBTL1GSK3B | |
| SCHEMBL13989365 | 0.82 | MAPT (0.41) | MAPTKDM4EGAAL3MBTL1GSK3B | |
| SCHEMBL13989294 | 0.81 | MAPT (0.47) | MAPTKDM4EGAAL3MBTL1GSK3B | |
| SCHEMBL13875697 | 0.80 | ALDH1A1 (0.51) | MAPTFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080319031-A1 | Novel Tyrosine Derivatives | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319031-A1 | Novel Tyrosine Derivatives | ABL1, LCK, TYRO3 | MAPT 2196/4885KDM4E 692/4885GAA 533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.